Licensing · GCC · Announced 8 Oct 2026
Alvion Pharmaceuticals → ADCAN Pharma
Licensing deal between Alvion Pharmaceuticals (Greece) and ADCAN Pharma (United Arab Emirates), announced 8 Oct 2026.
Parties: Alvion Pharmaceuticals P.C. (Greece) → ADCAN PHARMA (United Arab Emirates)
- Deal type
- Licensing
- Value
- Not stated
- Territory
- UAE, KSA and rest of Middle East (per umbrella terms)
- Therapeutic area
- Cardiovascular
- Asset
- Licensing and local manufacturing agreement — Alvion's added-value generics portfolio (stated categories: cardiovascular, diabetes, urinary, CNS); complex formulations including formulation-patented non-infringing generics
- Announced
- 8 Oct 2026
Our analysis
Why this matters
This deal buys formulation intelligence rather than volume.
Alvion's business model is developing complex, formulation-patented generics — products engineered to launch the day the originator's patent expires, protected by their own formulation patents — and licensing them to manufacturers in 40+ countries. ADCAN becomes Alvion's GCC licensee-manufacturer, gaining differentiated products that commodity generics makers cannot copy without infringing.
The full analysis is free to read with a work email on this page.
Source: ZAWYA